• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Raplon (rapacuronium bromide)

Audience: Hospital pharmacists, anesthesia professionals, wholesalers

Organon Inc. initiated a voluntary recall of Raplon (rapacuronium bromide) for injection. Several serious adverse events, including bronchospasm and unexplained fatalities, were reported during postmarketing surveillance (in each of these cases the cause was unknown, as there were multiple drugs administered and other conditions present). The posted letter is part of a package distributed by the manufacturer.

[March 29, 2001 - Letter - Organon, Inc.]